AUTL

Autolus Therapeutics
AUTL

$4.43
1.77%

Market Cap: 1.18B

 

About: Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Employees: 463

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 9 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

333% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 6

91% more call options, than puts

Call options by funds: $1.19M | Put options by funds: $625K

73% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 26

67% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 5 (+2) [Q1 2024]

50% more capital invested

Capital invested by funds: $745M [Q4 2023] → $1.12B (+$373M) [Q1 2024]

21% more funds holding

Funds holding: 96 [Q4 2023] → 116 (+20) [Q1 2024]

0.58% less ownership

Funds ownership: 66.47% [Q4 2023] → 65.89% (-0.58%) [Q1 2024]

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$8
81%
upside
Avg. target
$9.22
108%
upside
High target
$11
148%
upside

9 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Gil Blum
103%upside
$9
Buy
Reiterated
17 Jun 2024
Needham
Gil Blum
103%upside
$9
Buy
Reiterated
3 Jun 2024
Needham
Gil Blum
103%upside
$9
Buy
Reiterated
17 May 2024
Needham
Gil Blum
103%upside
$9
Buy
Reiterated
12 Apr 2024
Truist Securities
Gil Blum
148%upside
$11
Buy
Maintained
9 Apr 2024

Financial journalist opinion

Neutral
GlobeNewsWire
2 months ago
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) was selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago). ASCO Oral Presentation, abstract #6504: Title: Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX Phase Ib/II study Session Title: Oral Abstract Session – Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Session date and time: Friday, May 31, 2024, 14:45 – 17:45 EDT, 19:45 – 22:45 BST Presenting Author: Dr Elias Jabbour, Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX A conference call and webcast to discuss the presented data will be held at 9:30 am EDT/2:30 pm BST on Saturday June 1, 2024.
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO